FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra. Novo Nordisk’s American depositary receipts tumbled almost 6% ...
2-Year U.S. Treasury Note Continuous Contract $104.203-0.113-0.11% 5-Year U.S. Treasury Note Continuous Contract $110.164-0.242-0.22% 10-Year U.S. Treasury Note Continuous Contract $114.656-0.359 ...